Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial

被引：8

作者：

Khoo, Chee W. ^{[1
]}

Lip, Gregory Y. H. ^{[1
]}

机构：

[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 04期

关键词：

atrial fibrillation; dabigatran; direct thrombin inhibitor; stroke; DESIGN;

D O I：

10.1517/14656560903530691

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Oral anticoagulants such as warfarin have been used widely for the treatment of venous thromboembolism and stroke prevention in atrial fibrillation (AF) patients. Warfarin has significant limitations and also requires frequent monitoring. Thus, there is an unmet need, with the quest for alternative oral anticoagulants with stable pharmacokinetics and pharmacodynamics that do not need monitoring. The paper under evaluation provides us with up-to-date information on the safety and efficacy of a new oral anticoagulant, dabigatran, compared with warfarin for stroke prevention in AF patients.</.

引用

页码：685 / 687

页数：3

共 50 条

[1] Comparison of Dabigatran versus Warfarin in Diabetic Patients with Atrial Fibrillation: Results from the RE-LY Trial
Darius, Harald
Clemens, Andreas
Healey, Jeff S.
Avezum, Alvaro
Nagarakanti, Rangadham
Chin, Ashley
Noack, Herbert
Connolly, Stuart
CIRCULATION, 2012, 126 (21)
[2] Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial
Brambatti, Michela
Darius, Harald
Oldgren, Jonas
Clemens, Andreas
Noack, Herbert H.
Brueckmann, Martina
Yusuf, Salim
Wallentin, Lars
Ezekowitz, Michael D.
Connolly, Stuart J.
Healey, Jeff S.
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 196 : 127 - 131
[3] Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-ly Trial
Nagarakanti, Rangadham
Connolly, Stuart
Brueckmann, Martina
Hart, Robert G.
Reilly, Paul
Noack, Herbert
Clemens, Andreas
Wallentin, Lars
Yusuf, Salim
Ezekowitz, Michael D.
CIRCULATION, 2013, 128 (22)
[4] Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial
Coppens, Michiel
Eikelboom, John
Ezekowitz, Michael
Clemens, Andreas
Healy, Jeff
Wallentin, Lars
Noack, Herbert
Yusuf, Salim
Connolly, Stuart
CIRCULATION, 2012, 126 (21)
[5] Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)
Nagarakanti, Rangadham
Wallentin, Lars
Noack, Herbert
Brueckmann, Martina
Reilly, Paul
Clemens, Andreas
Connolly, Stuart J.
Yusuf, Salim
Ezekowitz, Michael D.
AMERICAN JOURNAL OF CARDIOLOGY, 2015, 116 (08): : 1204 - 1209
[6] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. Results of the RE-LY study
不详
KARDIOLOGIYA, 2009, 49 (10) : 75 - 76
[7] Efficacy and Safety of Dabigatran Versus Warfarin in Patients with Atrial Fibrillation: Analysis in Asian Population in RE-LY Trial
Hori, M.
Connolly, S. J.
Zhu, J.
Liu, L. S.
Lau, C-P
Pais, P.
Xavier, D.
Kim, S. S.
Omar, R.
Dans, A. L.
Tan, R. S.
Chen, J-H
Tanomsup, S.
Watanabe, M.
Koyanagi, M.
Ezekowitz, M. D.
Reilly, P. A.
Wallentin, L.
Yusuf, S.
CEREBROVASCULAR DISEASES, 2012, 34 : 9 - 9
[8] Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran The RE-LY Trial
Hart, Robert G.
Diener, Hans-Christoph
Yang, Sean
Connolly, Stuart J.
Wallentin, Lars
Reilly, Paul A.
Ezekowitz, Michael D.
Yusuf, Salim
STROKE, 2012, 43 (06) : 1511 - +
[9] Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial
DiNicolantonio, James J.
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1101 - 1111
[10] Efficacy and safety of dabigatran versus warfarin from the RE-LY trial
Avezum, Alvaro
de Figueiredo Oliveira, Gustavo Bernardes
Diaz, Rafael
Gonzalez Hermosillo, Jesus Antonio
Oldgren, Jonas
Ripoll, Ernesto Ferreiros
Noack, Herbert
Piegas, Leopoldo Soares
Connolly, Stuart J.
OPEN HEART, 2018, 5 (01):

← 1 2 3 4 5 →